Ibuprofen in Sepsis Study - Full Text View

Purpose

To determine the effects of ibuprofen on mortality, development and reversal of shock, and adult respiratory distress syndrome, and on Lung Parenchymal Injury Score in adult patients with serious infection.

Condition	Intervention	Phase
Acute Respiratory Distress Syndrome Lung Diseases Shock, Septic	Drug: ibuprofen	Phase III

MedlinePlus related topics:

Sepsis

Drug Information available for:

Ibuprofen Dexibuprofen

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control

Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date:	September 1990
Estimated Study Completion Date:	July 1995

Show Detailed Description

Eligibility

Ages Eligible for Study:	18 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Men and women patients with known or suspected sites of serious infection if core temperature was 38.3 degrees Celsius, heart rate 90 in the absence of beta-blockers, respiratory rate 20 or minute ventilation 10 liters per minute. In addition, one o

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000574

Sponsors and Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

Investigators


Investigator:	Gordon Bernard	Vanderbilt University

More Information

Publications:

Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP, Fulkerson WJ, Wright PE, Christman BW, Dupont WD, Higgins SB, Swindell BB. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med. 1997 Mar 27;336(13):912-8.

Study ID Numbers:	212
First Received:	October 27, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000574
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Systemic Inflammatory Response Syndrome

Ibuprofen

Sepsis

Respiratory Tract Diseases

Shock

Lung Diseases

Respiration Disorders

Respiratory Distress Syndrome, Adult

Shock, Septic

Acute respiratory distress syndrome

Inflammation

Additional relevant MeSH terms:

Anti-Inflammatory Agents

Disease

Molecular Mechanisms of Pharmacological Action

Cyclooxygenase Inhibitors

Physiological Effects of Drugs

Enzyme Inhibitors

Infection

Pharmacologic Actions

Pathologic Processes

Analgesics, Non-Narcotic

Sensory System Agents

Syndrome

Therapeutic Uses

Anti-Inflammatory Agents, Non-Steroidal

Analgesics

Peripheral Nervous System Agents

Antirheumatic Agents

Central Nervous System Agents

ClinicalTrials.gov processed this record on October 29, 2008

Sponsored by:	National Heart, Lung, and Blood Institute (NHLBI)
Information provided by:	National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier:	NCT00000574